Concord Wealth Partners Collegium Pharmaceutical, Inc Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Concord Wealth Partners holds 4 shares of COLL stock, worth $127. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4Holding current value
$127% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding COLL
# of Institutions
256Shares Held
37.2MCall Options Held
61.1KPut Options Held
5.8K-
Black Rock Inc. New York, NY5.79MShares$184 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY3MShares$95.3 Million2.57% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$83.9 Million1.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.25MShares$71.4 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA1.63MShares$51.9 Million0.01% of portfolio
About COLLEGIUM PHARMACEUTICAL, INC
- Ticker COLL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 34,126,200
- Market Cap $1.08B
- Description
- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...